Minerva

Minerva

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6651 (Published 19 October 2011) Cite this as: BMJ 2011;343:d6651
  1. Thomas M Jenkins, specialty registrar in neurology,
  2. M Reuber, reader in neurology and consultant neurologist
  1. 1Sheffield Institute of Translational Neuroscience, Sheffield S10 2HQ, UK; Royal Hallamshire Hospital, Sheffield S10 2JF

Although it is well known that rifampicin, an anti-tuberculous drug, …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe